Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Mark U. Rarick"'
Autor:
William R. Schelman, Tomislav Dragovich, Nathan Bahary, David P. Ryan, Joe Stephenson, Salvatore Del Prete, Mark U. Rarick, Hope E. Uronis, Stew Kroll, E. Gabriela Chiorean, Clarence Eng, Brian Ulrich, Peter Rosen, Darren Sigal, Mitesh J. Borad, Allen Lee Cohn, Shantan G. Reddy
Publikováno v:
Journal of Clinical Oncology. 33:1475-1481
Purpose TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreat
Autor:
Tatjana Kolevska, Normand Blais, J. von Pawel, Mark U. Rarick, S. Gadgeel, Alberto Chiappori, David R. Spigel, Joan H. Schiller, Martin Reck, Steven Hager, Bart Burington, Lowell L. Hart, Ekaterina Bassett
Publikováno v:
Annals of Oncology. 26:354-362
Imetelstat, a novel telomerase inhibitor, failed to improve significantly median PFS and OS as maintenance therapy (±bevacizumab) in advanced NSCLC. Telomere length (TL) biomarker results were consistent with the hypothesis that telomerase inhibitio
Autor:
Mark U. Rarick, Julia Bohlius, Alan E. Lichtin, Mark R. Somerfield, David Cella, David H. Regan, Charles L. Bennett, Jerome Seidenfeld, Karen L. Hagerty, Benjamin Djulbegovic, Matthew J. Goode, Ann A. Jakubowski, J. Douglas Rizzo
Publikováno v:
Journal of Clinical Oncology. 26:132-149
Purpose To update the American Society of Clinical Oncology/American Society of Hematology (ASCO/ASH) recommendations for the use of epoetin. The guideline was expanded to address use of darbepoetin and thromboembolic risk associated with these agent
Autor:
Alan E. Lichtin, David Cella, Charles L. Bennet, Ann A. Jakubowski, Julia Bohlius, Matthew J. Goode, David H. Regan, Douglas Rizzo, Mark U. Rarick, Benjamin Djullbegovic, Jerome Seidenfeld, Karen L. Hagerty, Mark R. Somerfield
Publikováno v:
Journal of Oncology Practice. 4:48-52
Autor:
Robert Dreicer, Celestia S. Higano, Mark U. Rarick, Joel Picus, Gary R. Hudes, Mansoor N. Saleh, Tomasz M. Beer, Alison L. Hannah, Louis Fehrenbacher
Publikováno v:
Investigational New Drugs. 25:565-570
Based on the pre-clinical spectrum of activity in taxane-resistant cell lines, we evaluated KOS-862 (epothilone D; 12,13-desoxyepothilone B) as second-line chemotherapy in androgen-independent prostate cancer.Thirty-eight men with metastatic androgen
Autor:
Lowell L. Hart, Ari D. Baron, Arthur H. Rosenberg, David E. McCune, Dennis M. Miller, Laurie E. Grove, Paul Swanson, Mark U. Rarick, Charles M. Rudin, Jonathan G. Drachman, Andrew D. Jacobs, Michael D. Thorn, Robert A. Figlin, Helen J. Ross
Publikováno v:
Lung Cancer. 54:69-77
Summary Purpose Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC). Targeted therapies may improve chemotherapy effectiveness without worsening
Autor:
George P. Browman, David Cella, Stephanie J. Lee, Michael S. Gordon, Alan E. Lichtin, Matthew J. Goode, Carole B. Miller, David H. Regan, Steven H. Woolf, Charles L. Bennett, Mark U. Rarick, Ann A. Jakubowski, Benjamin Djulbegovic, J. Douglas Rizzo, Jerome Seidenfeld
Publikováno v:
Blood. 100:2303-2320
ABSTRACT: Anemia resulting from cancer, or its treatment, is an important clinical problem increasingly treated with the recombinant hematopoietic growth factor erythropoietin. To address uncertainties regarding indications and efficacy, the American
Autor:
J. Douglas Rizzo, Mark R. Somerfield, Karen L. Hagerty, Jerome Seidenfeld, Julia Bohlius, Charles L. Bennett, David F. Cella, Benjamin Djulbegovic, Matthew J. Goode, Ann A. Jakubowski, Carole B. Miller, Mark U. Rarick, David H. Regan, Alan E. Lichtin
Publikováno v:
Journal of Clinical Oncology. 26:3098-3100
Autor:
Rami S. Komrokji, Stefan Faderl, Daruka Mahadevan, Naomi Galili, Gail L. Brown, Azra Raza, Mark U. Rarick, Deborah Mulford, Mikkael A. Sekeres, Alan F. List, John E. Godwin, Ralph V. Boccia, Han Myint, Dale G. Schaar, Scott E. Smith
Publikováno v:
Cancer. 118(8)
BACKGROUND: Ezatiostat is a glutathione analog prodrug glutathione S-transferase P1-1 (GSTP1-1) inhibitor. This study evaluated 2 extended dose schedules of oral ezatiostat in 89 heavily pretreated patients with low to intermediate-1 risk myelodyspla
Publikováno v:
American Journal of Hematology. 40:103-109
Three cases of thrombotic thrombocytopenic purpura (TTP) and coexistent human immunodeficiency virus (HIV) infection are presented with a review of 15 cases reported in the literature. Of the 18 total patients, one-half presented with no symptoms of